Bristol-Myers Squibb: all 2,184 studies
Page 17 of 22. Open to participants first (162), then studies with results posted, then the rest; newest registration first within each.
- A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis CNo longer availableNCT02161939
- Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in MyelomaWithdrawnNCT02155634Phase 3
- Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using PacemakersTerminatedNCT02153437Phase 1
- Early Post-marketing Study of Eliquis (Apixaban)WithdrawnNCT02153424
- Expanded Access Program With Nivolumab to Treat MelanomaNo longer availableNCT02142218
- Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in KoreaCompletedNCT02137629
- A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus NivolumabTerminatedNCT02124850Phase 1
- UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis CCompletedNCT02123654Phase 3
- Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female VolunteersCompletedNCT02117245
- Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMMCompletedNCT02112175Phase 3
- Absolute Bioavailability of BMS-791325CompletedNCT02112110Phase 1
- First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001CompletedNCT02110420Phase 1
- Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck CancerCompletedNCT02110082Phase 1
- Long Term Experience With Abatacept in Routine Clinical PracticeCompletedNCT02109666
- To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination TabletCompletedNCT02108639Phase 1
- Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and RosuvastatinCompletedNCT02104843Phase 1
- Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325CompletedNCT02103569Phase 1
- Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple MyelomaCompletedNCT02103335Phase 1
- Drug Interaction Study With RosuvastatinCompletedNCT02101125Phase 1
- Dose Ranging Study of RPC4046 in Eosinophilic EsophagitisCompletedNCT02098473Phase 2
- EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis CNo longer availableNCT02097966
- Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325CompletedNCT02095860Phase 1
- Long-term Experience With Abatacept SC in Routine Clinical PracticeCompletedNCT02090556
- Drug Interaction StatinCompletedNCT02089061Phase 1
- Alternative 10 mg/mL Liquid Formulation of ACY 1215 (Ricolinostat) in Healthy SubjectsCompletedNCT02088398Phase 1
- Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)CompletedNCT02085798
- Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy SubjectsCompletedNCT02084953Phase 1
- Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy SubjectsTerminatedNCT02079480Phase 1
- Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020CompletedNCT02068053Phase 1
- Ipilimumab 12-month Intensive Pharmacovigilance ProtocolCompletedNCT02050594
- Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect StudyCompletedNCT02049528Phase 1
- Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy SubjectsCompletedNCT02045966Phase 1
- Drug Interaction & Methadone & BuprenorphineCompletedNCT02045693Phase 1
- Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal InsufficiencyCompletedNCT02045017Phase 2
- Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life SettingCompletedNCT02037737
- 3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 CapsuleCompletedNCT02034773Phase 1
- Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular LymphomaTerminatedNCT02031419Phase 1
- A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.CompletedNCT02021500
- Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDSCompletedNCT02018926Phase 1/2
- To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy VolunteersCompletedNCT02017730Phase 1
- Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial FibrillationCompletedNCT02007655
- A Phase 1 QT Study in Healthy Male SubjectsCompletedNCT01986894Phase 1
- Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid TumorsTerminatedNCT01986218Phase 1
- UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic SubjectsCompletedNCT01979939Phase 3
- Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid ArthritisCompletedNCT01975610Phase 2
- UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated CirrhosisCompletedNCT01973049Phase 3
- Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)TerminatedNCT01947309
- Pharmacokinetic Study of Thalidomide in Subjects With Multiple MyelomaCompletedNCT01937442Phase 1
- Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic MelanomaWithdrawnNCT01933061Phase 2
- Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting StateCompletedNCT01930006Phase 1
- Phase 1 Study of CC-486 in Japanese Subjects With Hematological NeoplasmsTerminatedNCT01908387Phase 1
- CC-223 and Ketoconazole Drug-Drug Interaction StudyCompletedNCT01896323Phase 1
- Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney DiseaseCompletedNCT01886599Phase 1
- Eliquis Regulatory Post Marketing SurveillanceCompletedNCT01885598
- Eliquis Regulatory Post Marketing Surveillance (rPMS)CompletedNCT01885585
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy SubjectsCompletedNCT01858935Phase 1
- Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)Active, not recruitingNCT01838512
- Effect of SAR302503 on ECG Activity in Patients With Solid TumorsCompletedNCT01836705Phase 1
- Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired MalesCompletedNCT01835561Phase 1
- Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve PatientsWithdrawnNCT01797848Phase 3
- Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinCompletedNCT01795911Phase 2
- Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins LymphomaCompletedNCT01775631Phase 1
- Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal ImpairmentCompletedNCT01763190Phase 1
- Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic ImpairmentCompletedNCT01762462Phase 1
- Abatacept Post-marketing Clinical Study in JapanCompletedNCT01758198Phase 4
- Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis CCompletedNCT01754974Phase 3
- A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in TaiwanCompletedNCT01752075
- Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced TumorCompletedNCT01750580Phase 1
- Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT01744626Phase 1
- 2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy SubjectsCompletedNCT01733875Phase 1
- Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic LymphomaCompletedNCT01732861Phase 1
- A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)CompletedNCT01732848
- Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Naive CHB Patients in ChinaCompletedNCT01726439
- Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) TherapyCompletedNCT01718158Phase 3
- A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV SubjectsCompletedNCT01718145Phase 3
- Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy MalesCompletedNCT01712828Phase 1
- Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal DysfunctionCompletedNCT01708889Phase 1
- A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male SubjectsCompletedNCT01707407Phase 1
- Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic DisorderCompletedNCT01707394Phase 1
- Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort StudyWithdrawnNCT01694693
- Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With SplenomegalyCompletedNCT01692366Phase 2
- Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292CompletedNCT01692184Phase 1
- Connect® Myeloid Disease RegistryTerminatedNCT01688011
- Pattern Of Use Of Belatacept In US Transplant RecipientsCompletedNCT01670058
- Proof of Concept Study of BMS-823778 to Assess the Effects on AtherosclerosisWithdrawnNCT01666704Phase 2
- Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant RecipientsCompletedNCT01656343
- Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid TumorsCompletedNCT01653470Phase 1
- A Safety Study of BMS-852927 in Subjects With HypercholesterolemiaTerminatedNCT01651273Phase 1
- Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple MyelomaApproved for marketingNCT01632826
- Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid TumorsCompletedNCT01629758Phase 1
- Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis CWithdrawnNCT01629732Phase 2
- Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3CompletedNCT01616524Phase 3
- A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic DermatitisCompletedNCT01614756Phase 1
- A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult SubjectsCompletedNCT01611467Phase 1
- Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy SubjectsCompletedNCT01605994Phase 1
- Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI BackboneWithdrawnNCT01605084Phase 3
- Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese PatientsTerminatedNCT01602367Phase 2
- Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT01593410Phase 2
- Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on StatinsCompletedNCT01587365Phase 1
- Drug Interaction Study of SAR302503 in Patients With Solid TumorCompletedNCT01585623Phase 1